Guardant Health (NASDAQ:GH - Get Free Report) had its target price increased by research analysts at Mizuho from $60.00 to $65.00 in a report issued on Friday,Benzinga reports. The firm currently has an "outperform" rating on the stock. Mizuho's price objective would suggest a potential upside of 31.85% from the company's previous close.
A number of other research firms also recently commented on GH. Barclays boosted their price target on shares of Guardant Health from $55.00 to $60.00 and gave the stock an "overweight" rating in a research report on Thursday, May 1st. Stifel Nicolaus increased their price target on Guardant Health from $53.00 to $60.00 and gave the company a "buy" rating in a research note on Thursday, May 1st. JPMorgan Chase & Co. lifted their price target on Guardant Health from $50.00 to $55.00 and gave the company an "overweight" rating in a research report on Friday, February 21st. Morgan Stanley upped their price objective on Guardant Health from $42.00 to $52.00 and gave the company an "overweight" rating in a report on Thursday, March 6th. Finally, Guggenheim reaffirmed a "buy" rating and set a $56.00 target price on shares of Guardant Health in a report on Monday, February 24th. Twenty-one research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Guardant Health has a consensus rating of "Buy" and an average target price of $53.76.
Get Our Latest Report on Guardant Health
Guardant Health Trading Up 0.0%
NASDAQ:GH traded up $0.01 during mid-day trading on Friday, hitting $49.30. The stock had a trading volume of 1,666,663 shares, compared to its average volume of 2,129,194. The company has a 50 day simple moving average of $43.72 and a 200-day simple moving average of $41.65. The stock has a market capitalization of $6.11 billion, a price-to-earnings ratio of -13.85 and a beta of 1.37. Guardant Health has a 52 week low of $20.14 and a 52 week high of $52.92.
Guardant Health (NASDAQ:GH - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.57) by $0.08. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. The business had revenue of $203.47 million during the quarter, compared to analyst estimates of $189.91 million. During the same period in the prior year, the company posted ($0.46) EPS. The business's revenue for the quarter was up 20.8% compared to the same quarter last year. As a group, equities research analysts anticipate that Guardant Health will post -2.9 earnings per share for the current year.
Insider Buying and Selling at Guardant Health
In related news, CEO Amirali Talasaz sold 1,680 shares of the firm's stock in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $50.00, for a total transaction of $84,000.00. Following the transaction, the chief executive officer now owns 2,187,060 shares of the company's stock, valued at approximately $109,353,000. This trade represents a 0.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In the last quarter, insiders have sold 226,516 shares of company stock worth $11,226,549. 6.10% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of GH. SBI Securities Co. Ltd. acquired a new position in Guardant Health during the fourth quarter worth $43,000. SVB Wealth LLC bought a new position in shares of Guardant Health in the 1st quarter valued at approximately $54,000. Kimelman & Baird LLC acquired a new stake in Guardant Health in the 4th quarter worth approximately $58,000. NewEdge Advisors LLC raised its position in shares of Guardant Health by 13.5% in the fourth quarter. NewEdge Advisors LLC now owns 1,929 shares of the company's stock valued at $59,000 after purchasing an additional 230 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Guardant Health in the fourth quarter worth $61,000. Institutional investors own 92.60% of the company's stock.
About Guardant Health
(
Get Free Report)
Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.
Further Reading

Before you consider Guardant Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardant Health wasn't on the list.
While Guardant Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.